Research graph
References from Dual-Antigen CCHFV Vaccine Induces Neutralizing Immunity and Protection Against Lethal Challenge. Local targets link to admitted publications; unresolved targets remain external evidence.
10.1038/s41579-023-00871-9
10.1038/s41579-023-00871-9 · External reference
10.3389/fvets.2024.1513123
10.3389/fvets.2024.1513123 · External reference
10.1016/j.jinf.2022.09.007
10.1016/j.jinf.2022.09.007 · External reference
Determination of Seroprevalence and Risk Factors of Crimean–Congo Haemorrhagic Fever (CCHF) in the Endemic Region in Turkey: A Population-Based Cross-Sectional Study
2021 · External reference
10.1016/j.bjid.2025.104516
10.1016/j.bjid.2025.104516 · External reference
Crimean-Congo Hemorrhagic Fever Virus for Clinicians—Diagnosis, Clinical Management, and Therapeutics
2024 · External reference
Crimean-Congo Hemorrhagic Fever Virus for Clinicians—Virology, Pathogenesis, and Pathology
2024 · External reference
10.1002/14651858.cd012713.pub2
10.1002/14651858.cd012713.pub2 · External reference
Early use of ribavirin is beneficial in Crimean-Congo hemorrhagic fever
10.1089/vbz.2013.1421 · 2014 · External reference
10.1186/s12575-024-00244-3
10.1186/s12575-024-00244-3 · External reference
CCHFV vaccine development, current challenges, limitations, and future directions
10.3389/fimmu.2023.1238882 · 2023 · External reference
Crimean–Congo Hemorrhagic Fever Virus: Progress in Vaccine Development
10.3390/diagnostics13162708 · 2023 · External reference
10.1128/jvi.00752-06
10.1128/jvi.00752-06 · External reference
10.1038/s41467-024-46110-4
10.1038/s41467-024-46110-4 · External reference
10.1016/j.ebiom.2022.104188
10.1016/j.ebiom.2022.104188 · External reference
CD8+ T-cells target the Crimean-Congo haemorrhagic fever virus Gc protein to control the infection in wild-type mice
10.1016/j.ebiom.2023.104839 · 2023 · External reference
10.1016/j.cell.2021.05.001
10.1016/j.cell.2021.05.001 · External reference
10.1126/science.abl6502
10.1126/science.abl6502 · External reference
Nucleoside-Modified mRNA Vaccines Protect IFNAR–/– Mice against Crimean-Congo Hemorrhagic Fever Virus Infection
2022 · External reference
10.1186/1743-422x-5-7
10.1186/1743-422x-5-7 · External reference
A cynomolgus macaque model for Crimean-Congo haemorrhagic fever
10.1038/s41564-018-0141-7 · 2018 · External reference
10.7554/elife.63906
10.7554/elife.63906 · External reference
10.1038/s41541-024-01045-1
10.1038/s41541-024-01045-1 · External reference
Crimean Congo hemorrhagic fever virus nucleoprotein and GP38 subunit vaccine combination prevents morbidity in mice
10.1038/s41541-024-00931-y · 2024 · External reference
A CCHFV DNA vaccine protects against heterologous challenge and establishes GP38 as immunorelevant in mice
10.1038/s41541-021-00293-9 · 2021 · External reference
A DNA-based vaccine protects against Crimean-Congo haemorrhagic fever virus disease in a Cynomolgus macaque model
2021 · External reference
Single dose VSV-based vaccine protects mice against lethal heterologous Crimean-Congo hemorrhagic fever virus challenge
10.1038/s41541-025-01164-3 · 2025 · External reference
Antibodies targeting the Crimean-Congo Hemorrhagic Fever Virus nucleoprotein protect via TRIM21
10.1038/s41467-024-53362-7 · 2024 · External reference
10.1038/s41541-025-01310-x
10.1038/s41541-025-01310-x · External reference
Single dose, dual antigen RNA vaccines protect against lethal Crimean-Congo haemorrhagic fever virus infection in mice
10.1016/j.ebiom.2024.105017 · 2024 · External reference
10.1126/sciadv.aaw9535
10.1126/sciadv.aaw9535 · External reference
A Comparison of Plasmid DNA and mRNA as Vaccine Technologies
10.3390/vaccines7020037 · 2019 · External reference
10.1016/j.coi.2011.03.008
10.1016/j.coi.2011.03.008 · External reference
10.1371/journal.pone.0019252
10.1371/journal.pone.0019252 · External reference
The use of electroporation to deliver DNA-based vaccines
10.1080/14760584.2023.2292772 · 2024 · External reference
10.1073/pnas.2110817118
10.1073/pnas.2110817118 · External reference
10.1038/nrd.2017.243
10.1038/nrd.2017.243 · External reference
10.1016/j.immuni.2021.11.001
10.1016/j.immuni.2021.11.001 · External reference
10.1080/21645515.2023.2281733
10.1080/21645515.2023.2281733 · External reference
10.1016/j.omta.2026.201710 · Admitted local publication
10.1016/s0140-6736(26)00512-x
10.1016/s0140-6736(26)00512-x · External reference
Lipid nanoparticles (LNP) induce activation and maturation of antigen presenting cells in young and aged individuals
10.1038/s42003-023-04555-1 · 2023 · External reference
10.1101/2021.03.04.430128
10.1101/2021.03.04.430128 · External reference
10.1016/j.vaccine.2023.06.009
10.1016/j.vaccine.2023.06.009 · External reference
Formulation and Delivery Technologies for mRNA Vaccines
2022 · External reference
10.1089/blr.2007.9905
10.1089/blr.2007.9905 · External reference
Intradermal-delivered DNA vaccine induces durable immunity mediating a reduction in viral load in a rhesus macaque SARS-CoV-2 challenge model
10.1016/j.xcrm.2021.100420 · 2021 · External reference
10.1111/jmp.12123
10.1111/jmp.12123 · External reference
Comparison of antibody response durability of mRNA-1273, BNT162b2, and Ad26.COV2.S SARS-CoV-2 vaccines in healthcare workers
10.1016/j.ijid.2022.08.022 · 2022 · External reference
Durability and determinants of anti-SARS-CoV-2 spike antibodies following the second and third doses of mRNA COVID-19 vaccine
2023 · External reference
Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial
10.1016/s0140-6736(15)00239-1 · 2015 · External reference
Plasmid DNA Manufacturing for Indirect and Direct Clinical Applications
10.1089/hum.2017.159 · 2017 · External reference
Vaccine process technology—A decade of progress
10.1002/bit.28703 · 2024 · External reference
10.1016/j.trsl.2021.11.009
10.1016/j.trsl.2021.11.009 · External reference
Distinct roles of vaccine-induced SARS-CoV-2-specific neutralizing antibodies and T cells in protection and disease
10.1016/j.ymthe.2024.01.007 · 2024 · External reference
A universal SARS-CoV DNA vaccine inducing highly cross-reactive neutralizing antibodies and T cells
2022 · External reference
10.1128/jvi.03691-14
10.1128/jvi.03691-14 · External reference
10.1038/srep26637
10.1038/srep26637 · External reference
